We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+36.58%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$1.1B
AUM Growth
+$322M
Cap. Flow
+$127M
Cap. Flow %
11.55%
Top 10 Hldgs %
71.51%
Holding
31
New
7
Increased
13
Reduced
4
Closed
4

Top Buys

Rank Stock Value
1
SUPN icon
Supernus Pharmaceuticals
SUPN
+$33.7M
2
ABBV icon
AbbVie
ABBV
+$29.6M
3
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$20.9M
4
HPTX
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
+$19.5M
5
CPRX
Catalyst Pharmaceutical
CPRX
+$17.5M

Top Sells

Rank Stock Value
1
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$27.2M
2
HSTM icon
HealthStream
HSTM
+$9.46M
3
EVDY
Everyday Health, Inc.
EVDY
+$9.34M
4
OPCH icon
Option Care Health
OPCH
+$8.23M
5
OSIR
Osiris Therapeutics, Inc. Common Stock
OSIR
+$8M

Sector Composition

Rank Sector Weight
1 Healthcare 69.95%
2 Financials 0.05%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
1
United Therapeutics
UTHR
$26.2B
$123M 11.18%
712,186
+52,000
+8% +$7.93M
AKRX
2
DELISTED
Akorn Inc
AKRX
$92.1M 8.39%
1,938,485
+255,000
+15% +$11.6M
HPTX
3
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
$87.3M 7.95%
1,901,930
+650,577
+52% +$19.5M
CSII
4
DELISTED
Cardiovascular Systems, Inc.
CSII
$85.6M 7.79%
2,192,500
+57,300
+3% +$1.97M
INSY
5
DELISTED
Insys Therapeutics, Inc.
INSY
$79M 7.19%
2,718,494
+210,000
+8% +$5.55M
TVTX icon
6
Travere Therapeutics
TVTX
$5.33B
$74.5M 6.78%
3,107,710
+556,175
+22% +$8.48M
ANIP icon
7
ANI Pharmaceuticals
ANIP
$1.83B
$70.3M 6.41%
1,124,667
+34,600
+3% +$2.1M
ABBV icon
8
AbbVie
ABBV
$455B
$69M 6.28%
1,177,900
+490,000
+71% +$29.6M
OFIX icon
9
Orthofix Medical
OFIX
$477M
$56.7M 5.16%
1,580,218
+143,723
+10% +$4.52M
ANAC
10
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$48M 4.37%
830,151
-639,539
-44% -$27.2M
ENTA icon
11
Enanta Pharmaceuticals
ENTA
$378M
$47.6M 4.33%
1,552,962
-143,185
-8% -$5.57M
SUPN icon
12
Supernus Pharmaceuticals
SUPN
$2.65B
$43.1M 3.93%
+3,566,923
New +$33.7M
PTX
13
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$34.9M 3.17%
326,148
-16,631
-5% -$1.59M
TVTY
14
DELISTED
Tivity Health, Inc. Common Stock
TVTY
$33.8M 3.08%
1,716,307
+399,814
+30% +$8.36M
EGRX
15
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$30.8M 2.81%
+735,922
New +$20.9M
OSIR
16
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
$21.1M 1.92%
1,198,336
-476,225
-28% -$8M
CPRX
17
DELISTED
Catalyst Pharmaceutical
CPRX
$21M 1.91%
+4,849,870
New +$17.5M
DSCI
18
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$13.8M 1.26%
1,632,627
– –
EPRS
19
DELISTED
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
$13.6M 1.24%
+1,523,773
New +$12.2M
PACB icon
20
Pacific Biosciences
PACB
$460M
$11.7M 1.07%
+2,002,971
New +$13.8M
PLX icon
21
Protalix BioTherapeutics
PLX
$183M
$10M 0.91%
564,375
+56,641
+11% +$1.11M
ADMA icon
22
ADMA Biologics
ADMA
$2.01B
$9.67M 0.88%
986,507
+109,100
+12% +$1.1M
VCEL icon
23
Vericel Corp
VCEL
$2.43B
$8.71M 0.79%
2,352,940
– –
LCTX icon
24
Lineage Cell Therapeutics
LCTX
$277M
$7.96M 0.73%
1,985,579
– –
MSLI
25
DELISTED
Merus Labs International Inc.
MSLI
$2.87M 0.26%
1,368,614
+8,400
+0.6% +$15.5K
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q1 2015 Portfolio in Review

As of Q1 2015, Consonance Capital Management held 31 positions worth $1.1B, up 41% from $776M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Consonance Capital Management deployed $127M of net new capital in Q1 2015, opening 7 new positions and adding to 13 existing holdings. Its largest new stake was Supernus Pharmaceuticals: 3,566,923 shares worth $43.1M.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, down from 72% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was ANACOR PHARMACEUTICALS INC COM, an estimated $27.2M trimmed.

  • Consonance Capital Management's largest Q1 2015 buy was Supernus Pharmaceuticals: 3,566,923 shares worth $43.1M.
  • Consonance Capital Management added most to AbbVie in Q1 2015, an estimated $29.6M increase.
  • Consonance Capital Management's biggest Q1 2015 reduction was ANACOR PHARMACEUTICALS INC COM, cutting an estimated $27.2M.
  • Consonance Capital Management fully exited HealthStream in Q1 2015, selling an estimated $9.46M.
  • Consonance Capital Management's ten largest holdings make up 72% of its $1.1B portfolio in Q1 2015.
  • Consonance Capital Management opened 7 new positions and closed 4 in Q1 2015.
  • Consonance Capital Management's portfolio value rose 41% quarter-over-quarter to $1.1B.

Based on Consonance Capital Management's 13F filing for Q1 2015, filed 14 May 2015.